Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy for invasive bladder tumors.

H I Scher1

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, N.Y.

Progress in Clinical and Biological Research
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.

European journal of cancer (Oxford, England : 1990)·2021
Same author

Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Periprostatic adipose inflammation is associated with high-grade prostate cancer.

Prostate cancer and prostatic diseases·2017
Same author

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium.

Clinical pharmacology and therapeutics·2017

Chemotherapy shows promise for invasive bladder cancer, potentially enabling bladder preservation in some cases. Further research into systemic therapies is crucial for improving long-term survival outcomes.

Area of Science:

  • Urology
  • Medical Oncology

Background:

  • Chemotherapy's role in invasive bladder cancer is evolving, with varying treatment goals based on disease stage.
  • Bladder preservation is a consideration for minimally advanced disease (T2, T3a), while higher stages focus on micrometastasis treatment.

Purpose of the Study:

  • To evaluate the potential of chemotherapy in managing invasive bladder cancer.
  • To explore the feasibility of bladder preservation and its impact on treatment strategies.
  • To assess the validity of survival as an endpoint in clinical trials for advanced bladder cancer.

Main Methods:

  • Review of phase II trial data to identify treatment leads.
  • Analysis of treatment approaches for different stages of bladder cancer, including radical surgery and bladder preservation.

Related Experiment Videos

  • Consideration of the impact of ileo neo-bladders on patient and physician decisions regarding definitive therapy.

    • Main Results:

    • Chemotherapy does not negate the need for definitive local therapy, even with bladder preservation possibilities.
    • Ileo neo-bladders may improve quality of life but do not alter the disease's natural history.
    • Selected patients with advanced disease can achieve long-term survival with chemotherapy alone, supporting survival as a clinical trial endpoint.

    Conclusions:

    • Neoadjuvant chemotherapy is investigational and requires further study for invasive bladder cancer.
    • More effective systemic therapies are needed to significantly impact the natural history of invasive bladder cancer.
    • Physicians are encouraged to enroll patients in clinical trials despite potential reluctance.